Company / EPS (Diluted)
Enliven Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.89
FY2024
5-year range
-$12.05 / -$1.89
FY2021-FY2024
Trend
+6.0%
vs FY2023
Sector context
#115 of 204
Health Care
What the data says
At $-1.89, Enliven Therapeutics, Inc.'s eps (diluted) ranks #115 of 204 in the Health Care sector. Improved from $-12.05 to $-1.89 over the past 2 years.
Based on SEC 10-K filings.
-1.89 in FY2024.
Improved from $-12.05 to $-1.89 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#115 of 204 in Health CareTop 56% of 204This company -$1.89 Sector average -$0.98
▼
-92.9% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 6.0% year-over-year.
- Ranks #115 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.89 | +6.0% |
| FY2023 | -$2.01 | +83.3% |
| FY2022 | -$12.05 | -408.4% |
| FY2021 | -$2.37 | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026